The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology
Autor: | Bradley T. Christian, Anne M. Fagan, Alzheimer's Biomarker Consortium‐Down Syndrome, Sharon J. Krinsky-McHale, Sid E. O'Bryant, Sigan L. Hartley, Mei-Cheng Wang, H. Diana Rosas, William E. Klunk, Mark Mapstone, Nicole Schupf, Adam M. Brickman, Ira T. Lott, Florence Lai, Elizabeth Head, Howard Andrews, Shahid Zaman, Dana L. Tudorascu, Annie Cohen, Beau M. Ances, Benjamin L. Handen, Joseph H. Lee, Wayne Silverman |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Down syndrome Longitudinal study Population Disease Neuropathology Review Article lcsh:Geriatrics lcsh:RC346-429 03 medical and health sciences 0302 clinical medicine Neuroimaging medicine Dementia education Psychiatry Review Articles ABC‐DS lcsh:Neurology. Diseases of the nervous system 030304 developmental biology 0303 health sciences education.field_of_study business.industry Alzheimer's disease medicine.disease Psychiatry and Mental health lcsh:RC952-954.6 Biomarker (medicine) Neurology (clinical) business 030217 neurology & neurosurgery dementia |
Zdroj: | Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 12, Iss 1, Pp n/a-n/a (2020) |
ISSN: | 2352-8729 |
Popis: | Author(s): Handen, Benjamin L; Lott, Ira T; Christian, Bradley T; Schupf, Nicole; OBryant, Sid; Mapstone, Mark; Fagan, Anne M; Lee, Joseph H; Tudorascu, Dana; Wang, Mei-Cheng; Head, Elizabeth; Klunk, William; Ances, Beau; Lai, Florence; Zaman, Shahid; Krinsky-McHale, Sharon; Brickman, Adam M; Rosas, H Diana; Cohen, Annie; Andrews, Howard; Hartley, Sigan; Silverman, Wayne; Alzheimer's Biomarker Consortium‐Down Syndrome (ABC‐DS) | Abstract: IntroductionAdults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments.MethodsWe describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression.ResultsApproximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided.DiscussionThis represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population. |
Databáze: | OpenAIRE |
Externí odkaz: |